Search results for "NOE"

showing 10 items of 825 documents

Immunotherapy of colorectal cancer: New perspectives after a long path

2016

Although significant therapeutic improvement has been achieved in the last 10 years, the survival of metastatic colorectal cancer patients remains in a range of 28 to 30 months. Presently, systemic treatment includes combination chemotherapy with oxaliplatin and/or irinotecan together with a backbone of 5-fluorouracil/levofolinate, alone or in combination with monoclonal antibodies to VEGFA (bevacizumab) or EGF receptor (cetuximab and panitumumab). The recent rise of immune checkpoint inhibitors in the therapeutic scenario has renewed scientific interest in the investigation of immunotherapy in metastatic colorectal cancer patients. According to our experience and view, here, we review the…

0301 basic medicineOncologymedicine.medical_specialtyBevacizumabColorectal cancermedicine.medical_treatmentImmunologycolorectal cancerthymidylate synthasechemotherapyCancer Vaccines03 medical and health sciences0302 clinical medicineCostimulatory and Inhibitory T-Cell ReceptorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansPanitumumabImmunology and AllergyMolecular Targeted Therapyimmune-modulating strategieImmunotherapy metastatic colorectal cancer monoclonal antibodies target therapyCetuximabbusiness.industrytarget therapymetastatic colorectal cancercarcinoembryonic antigenAntibodies MonoclonalCancerCombination chemotherapyimmune-modulating strategiesImmunotherapymedicine.diseaseCombined Modality Therapy030104 developmental biologyOncology030220 oncology & carcinogenesisCancer vaccineImmunotherapymonoclonal antibodiesColorectal Neoplasmsbusinesscancer vaccinemedicine.drug
researchProduct

Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence

2016

Bladder cancer has an unexplained, high recurrence rate. Causes of recurrence might include the presence of sporadic tumor micro-foci in the residual urothelial tissue after surgery associated with an inverted ratio between intratumoral effector and regulatory T cell subsets. Hence, surgical specimens of both tumors and autologous, macroscopically/histologically free-of-tumor tissues were collected from 28 and 20 patients affected by bladder or renal cancer, respectively. The frequencies of effector (IFNγ+ and IL17+ T cells) and regulatory (CD4+CD25hiCD127lo and CD8+CD28-CD127loCD39+ Treg) T cell subpopulations among tumor infiltrating lymphocytes were analyzed by immunofluorescence, while …

0301 basic medicinePathologyNeoplasm ResidualT-LymphocytesMessengerImmunoenzyme TechniqueFluorescent Antibody TechniqueCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryImmunoenzyme TechniquesTh10302 clinical medicineLymphocytesReverse Transcriptase Polymerase Chain ReactionResearch Paper: ImmunologyPrognosisRegulatoryBladder cancer; Immune response; Immunity; Immunology and microbiology section; Mage; Th1; Th17; Tumor infiltrating lymphocytes; CD8-Positive T-Lymphocytes; Case-Control Studies; Fluorescent Antibody Technique; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphocytes Tumor-Infiltrating; Melanoma-Specific Antigens; Neoplasm Grading; Neoplasm Proteins; Neoplasm Recurrence Local; Neoplasm Staging; Neoplasm Residual; Prognosis; RNA Messenger; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes Regulatory; Urinary Bladder Neoplasms; OncologyNeoplasm Proteinsmedicine.anatomical_structureLocalOncologytumor infiltrating lymphocytesResidual030220 oncology & carcinogenesisImmunology and Microbiology Sectionbladder cancerTh17Case-Control StudieMelanoma-Specific AntigenMelanoma-Specific AntigensHumanmedicine.medical_specialtyPrognosiRegulatory T cellT cellReal-Time Polymerase Chain ReactionMAGEFollow-Up StudieNeoplasm Protein03 medical and health sciencesLymphocytes Tumor-InfiltratingImmune systemAntigenmedicineHumansTumor-InfiltratingRNA MessengerImmune responseNeoplasm StagingBladder cancerTumor-infiltrating lymphocytesbusiness.industryImmunityCD8-Positive T-LymphocyteT lymphocytemedicine.diseaseNeoplasm Recurrence030104 developmental biologyUrinary Bladder NeoplasmsCase-Control StudiesNeoplasmRNANeoplasm GradingNeoplasm Recurrence Localtumor infiltrating lymphocytebusinessCD8Follow-Up StudiesOncotarget
researchProduct

Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease

2016

International audience; Mutations in leucine-rich repeat kinase 2 (LRRK2) cause late-onset, autosomal dominant familial Parkinsons disease (PD) and variation at the LRRK2 locus contributes to the risk for idiopathic PD. LRRK2 can function as a protein kinase and mutations lead to increased kinase activity. To elucidate the pathophysiological mechanism of the R1441C mutation in the GTPase domain of LRRK2, we expressed human wild-type or R1441C LRRK2 in dopaminergic neurons of Drosophila and observe reduced locomotor activity, impaired survival and an age-dependent degeneration of dopaminergic neurons thereby creating a new PD-like model. To explore the function of LRRK2 variants in vivo, we …

0301 basic medicineProteomerab3 GTP-Binding Proteinsalpha-synucleindomainSyntaxin 1Interactomedopaminergic-neuronsAnimals Genetically Modifiedchemistry.chemical_compound0302 clinical medicinemicrotubule stabilityDrosophila ProteinsProtein Interaction MapsGenetics (clinical)LRRK2 GeneKinasephosphorylationBrainParkinson DiseaseArticlesGeneral Medicineautosomal-dominant parkinsonismLRRK2Drosophila melanogasterSynaptotagmin IProteomePhosphorylationSynaptic VesiclesNerve Tissue ProteinsBiologyLeucine-Rich Repeat Serine-Threonine Protein Kinase-203 medical and health sciencesGeneticsAnimalsHumansKinase activitygeneMolecular BiologyAlpha-synucleingtp-bindingDopaminergic Neuronsrepeat kinase 2Molecular biologyPhosphoric Monoester Hydrolasesnervous system diseasesDisease Models Animal030104 developmental biologyGene Expression Regulationchemistrymutation030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions

2016

Cabozantinib, a c-MET and vascular endothelial growth factor receptor 2 inhibitor, demonstrated to prolong progression free survival and improve skeletal disease-related endpoints in castration-resistant prostate cancer and in metastatic renal carcinoma. Our purpose is to investigate the direct effect of cabozantinib on bone microenvironment using a total human model of primary osteoclasts and osteoblasts.Osteoclasts were differentiated from monocytes isolated from healthy donors; osteoblasts were derived from human mesenchymal stem cells obtained from bone fragments of orthopedic surgery patients. Osteoclast activity was evaluated by tartrate resistant acid phosphatase (TRAP) staining and …

0301 basic medicinePyridines -- pharmacologyPyridinesPyridineImmunoenzyme TechniqueOsteoclastsApoptosisRANK Ligand -- genetics -- metabolismImmunoenzyme Techniqueschemistry.chemical_compoundBone Resorption -- drug therapy -- metabolism -- pathology0302 clinical medicineOsteogenesisCathepsin KMedicineAnilidesAnilides -- pharmacologyOsteoprotegerin -- genetics -- metabolismOsteoclasts -- cytology -- drug effects -- physiologyHuman primary cellCells CulturedTartrate-resistant acid phosphataseReceptor Activator of Nuclear Factor-kappa B -- genetics -- metabolismbiologyProto-Oncogene Proteins c-met -- genetics -- metabolismReceptor Activator of Nuclear Factor-kappa BReverse Transcriptase Polymerase Chain ReactionOsteoblastOsteogenesiOsteoblastCell DifferentiationSciences bio-médicales et agricolesProto-Oncogene Proteins c-metOsteoblasts -- cytology -- drug effects -- physiologymedicine.anatomical_structureCell Differentiation -- drug effectsOncologyRANKL030220 oncology & carcinogenesishuman primary cellsOsteoclastosteoprotegerin (OPG)bone microenvironmentHumanResearch Papermusculoskeletal diseasesmedicine.medical_specialtyCabozantinibBlotting WesternOsteogenesis -- drug effects -- physiologyReal-Time Polymerase Chain ReactionBone resorption03 medical and health sciencesOsteoprotegerinOsteoclastcabozantinibInternal medicineHumansRNA MessengerBone ResorptionCell ProliferationOsteoblastsbusiness.industryRANK LigandAnilideOsteoprotegerinApoptosiBone microenvironment; Cabozantinib; Human primary cells; Osteoprotegerin (OPG); Receptor activator of nuclear factor-kb ligand (RANKL); Anilides; Apoptosis; Blotting Western; Bone Resorption; Cell Differentiation; Cell Proliferation; Cells Cultured; Humans; Immunoenzyme Techniques; Osteoblasts; Osteoclasts; Osteogenesis; Osteoprotegerin; Proto-Oncogene Proteins c-met; Pyridines; RANK Ligand; RNA Messenger; Real-Time Polymerase Chain Reaction; Receptor Activator of Nuclear Factor-kappa B; Reverse Transcriptase Polymerase Chain Reaction; Oncology030104 developmental biologyEndocrinologychemistrybiology.proteinbusinessRNA Messenger -- geneticsreceptor activator of nuclear factor-kb ligand (RANKL)
researchProduct

Usherin defects lead to early-onset retinal dysfunction in zebrafish

2018

Mutations in USH2A are the most frequent cause of Usher syndrome and autosomal recessive nonsyndromic retinitis pigmentosa. To unravel the pathogenic mechanisms underlying USH2A-associated retinal degeneration and to evaluate future therapeutic strategies that could potentially halt the progression of this devastating disorder, an animal model is needed. The available Ush2a knock-out mouse model does not mimic the human phenotype, because it presents with only a mild and late-onset retinal degeneration. Using CRISPR/Cas9-technology, we introduced protein-truncating germline lesions into the zebrafish ush2a gene (ush2a(rmc1): c.2337_2342delinsAC; p.Cys780GlnfsTer32 and ush2a(b1245): c.15520_…

0301 basic medicineRetinal degenerationGenotyping TechniquesUsher syndrome2804 Cellular and Molecular NeuroscienceApoptosis030105 genetics & heredityBiologyArticleRetinaGermlineSensory disorders Donders Center for Medical Neuroscience [Radboudumc 12]Gene Knockout Techniques03 medical and health sciencesCellular and Molecular NeuroscienceUSH2 complex2809 Sensory SystemsAll institutes and research themes of the Radboud University Medical CenterRetinitis pigmentosaElectroretinographymedicineotorhinolaryngologic diseasesJournal ArticleAnimalsMicroscopy ImmunoelectronZebrafishZebrafishExtracellular Matrix ProteinsRetinal DegenerationMembrane ProteinsZebrafish ProteinsRetinal Photoreceptor Cell Outer Segmentmedicine.diseasebiology.organism_classification2731 OphthalmologySensory Systems10124 Institute of Molecular Life SciencesCell biologyDisease Models AnimalOphthalmology030104 developmental biologyGene Expression RegulationEctodomainMutation570 Life sciences; biologyXenotropic and Polytropic Retrovirus ReceptorUsher SyndromesErg
researchProduct

Rett Syndrome Mutant Neural Cells Lacks MeCP2 Immunoreactive Bands.

2016

Dysfunctions of MeCP2 protein lead to various neurological disorders such as Rett syndrome and Autism. The exact functions of MeCP2 protein is still far from clear. At a molecular level, there exist contradictory data. MeCP2 protein is considered a single immunoreactive band around 75 kDa by western-blot analysis but several reports have revealed the existence of multiple MeCP2 immunoreactive bands above and below the level where MeCP2 is expected. MeCP2 immunoreactive bands have been interpreted in different ways. Some researchers suggest that multiple MeCP2 immunoreactive bands are unidentified proteins that cross-react with the MeCP2 antibody or degradation product of MeCP2, while others…

0301 basic medicineThreonineHeredityMethyl-CpG-Binding Protein 2Genetic LinkageMutantFluorescent Antibody TechniqueSocial Scienceslcsh:MedicinePC12 CellsBiochemistryEpitopeImmunoenzyme TechniquesCell FusionNeuroblastomaFluorescence MicroscopyAnimal CellsMedicine and Health SciencesPsychologyPost-Translational ModificationPhosphorylationAmino Acidslcsh:ScienceCells CulturedCross ReactivityNeuronsStainingMicroscopyMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionOrganic CompoundsCell StainingLight MicroscopyTransfectionChemistryX-Linked TraitsSex LinkagePhysical SciencesCellular TypesResearch ArticleCell signalingCell Physiologycongenital hereditary and neonatal diseases and abnormalitiesBlotting WesternImmunologyRett syndromeBiologyReal-Time Polymerase Chain ReactionResearch and Analysis MethodsMECP203 medical and health sciencesNeurologiaAntigenHydroxyl Amino Acidsmental disordersmedicineRett SyndromeGeneticsAnimalsHumansRNA MessengerClinical GeneticsHEK 293 cellsOrganic Chemistrylcsh:RChemical CompoundsBiology and Life SciencesProteinsCell Biologymedicine.diseaseMolecular biologyRatsnervous system diseases030104 developmental biologyHEK293 CellsSpecimen Preparation and TreatmentCellular NeuroscienceMutationDevelopmental PsychologyMalaltieslcsh:QNeuroscience
researchProduct

CO2 flux emissions from the Earth's most actively degassing volcanoes, 2005-2015

2019

AbstractThe global carbon dioxide (CO2) flux from subaerial volcanoes remains poorly quantified, limiting our understanding of the deep carbon cycle during geologic time and in modern Earth. Past attempts to extrapolate the global volcanic CO2 flux have been biased by observations being available for a relatively small number of accessible volcanoes. Here, we propose that the strong, but yet unmeasured, CO2 emissions from several remote degassing volcanoes worldwide can be predicted using regional/global relationships between the CO2/ST ratio of volcanic gases and whole-rock trace element compositions (e.g., Ba/La). From these globally linked gas/rock compositions, we predict the CO2/ST gas…

0301 basic medicineVolcanologylcsh:MedicineAtmospheric sciencesCarbon cycleVolcanic Gases03 medical and health scienceschemistry.chemical_compound0302 clinical medicine[SDU.STU.VO]Sciences of the Universe [physics]/Earth Sciences/Volcanologyeventlcsh:Scienceevent.disaster_typeCarbon dioxide in Earth's atmospheregeographyMultidisciplinarygeography.geographical_feature_categoryAtmospheric carbon dioxidelcsh:RTrace elementFOS: Earth and related environmental sciencesVolcanologyGeochemistry030104 developmental biologyVolcanochemistry[SDU]Sciences of the Universe [physics]Carbon dioxideSubaerialEnvironmental scienceVolcanoeslcsh:Q030217 neurology & neurosurgeryvolcanic gas fluxes voclanoes
researchProduct

Current advances in γδ T cell-based tumor immunotherapy

2017

γδ T cells are a minor population (~5%) of CD3 T cells in the peripheral blood, but abound in other anatomic sites such as the intestine or the skin. There are two major subsets of γδ T cells: those that express Vd1 gene, paired with different Vγ elements, abound in the intestine and the skin, and recognize the major histocompatibility complex (MHC) class I-related molecules such as MHC class I-related molecule A, MHC class I-related molecule B, and UL16-binding protein expressed on many stressed and tumor cells. Conversely, γδ T cells expressing the Vδ2 gene paired with the Vγ9 chain are the predominant (50-90%) γδ T cell population in the peripheral blood and recognize phosphoant…

0301 basic medicinelcsh:Immunologic diseases. AllergyAdoptive cell transferadoptive transferT cellImmunologyReviewBiologyMajor histocompatibility complexγδ T cells03 medical and health sciencesInterleukin 210302 clinical medicineAdoptive transfer; Immunoevasion; Immunotherapy; Zoledronate; γδ T cells; Immunology and Allergy; ImmunologyMHC class ImedicineCytotoxic T cellImmunology and AllergyAdoptive transfer Immunoevasion Immunotherapy Zoledronate γδ T cellsGamma delta T cellγδ T cellMHC restriction030104 developmental biologymedicine.anatomical_structureImmunologybiology.proteinimmunoevasionimmunotherapylcsh:RC581-607030215 immunologyZoledronate
researchProduct

Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis

2016

BACKGROUND Fibrosis as a common problem in patients with Crohn's disease is a result of an imbalance toward excessive tissue repair. At present, there is no specific treatment option. Pirfenidone is approved for the treatment of idiopathic pulmonary fibrosis with both antifibrotic and anti-inflammatory effects. We subsequently investigated the impact of pirfenidone treatment on development of fibrosis in a new mouse model of intestinal fibrosis. METHODS Small bowel resections from donor mice were transplanted subcutaneously into the neck of recipients. Animals received either pirfenidone (100 mg/kg, three times daily, orally) or vehicle. RESULTS After administration of pirfenidone, a signif…

0301 basic medicinemedicine.medical_specialtyPyridonesBlotting Western610 Medicine & healthGastroenterologyImmunoenzyme TechniquesMice03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineTransforming Growth Factor betaFibrosis10049 Institute of Pathology and Molecular PathologyInternal medicinemedicineAnimalsImmunology and Allergy2715 GastroenterologyCell ProliferationMice Inbred BALB CbiologyCell growthbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologyPirfenidoneTransforming growth factor betamedicine.diseaseFibrosisMice Inbred C57BLTransplantationBlotDisease Models AnimalIntestinal Diseases10219 Clinic for Gastroenterology and Hepatology030104 developmental biology2723 Immunology and Allergybiology.proteinFemale030211 gastroenterology & hepatologyCollagen10069 Clinic of Cranio-Maxillofacial SurgerybusinessAfter treatmentmedicine.drugInflammatory Bowel Diseases
researchProduct

Corticoperipheral neuromuscular disconnection in obstructive sleep apnoea.

2020

Abstract The roles of central nervous mechanisms and cortical output in obstructive sleep apnoea remain unclear. We addressed corticomuscular coupling between cortical sensorimotor areas and lower facial motor units as a mechanistic pathway and as a possible surrogate marker of corticoperipheral motor control in obstructive sleep apnoea. In this exploratory cross-sectional retrospective study, we analysed EEG (C3 and C4 leads) and chin EMG from polysomnography recordings in 86 participants (22 females; age range: 26–81 years): 27 with mild (respiratory disturbance index = 5–15 events/h), 21 with moderate (15–30 events/h) and 23 with severe obstructive sleep apnoea (>30 events/h) and 15 cont…

0301 basic medicinemedicine.medical_specialtyobstructive sleep apnoeacorticalPolysomnography03 medical and health sciences0302 clinical medicineInternal medicineRespiratory disturbance indexmedicinecouplingSleep Stagesmedicine.diagnostic_testbusiness.industryGeneral EngineeringMotor controlmedicine.diseasemotorMotor unitObstructive sleep apneaAutonomic nervous system030104 developmental biologyBreathingCardiologyOriginal Articleneuromuscularbusiness030217 neurology & neurosurgeryBrain communications
researchProduct